Clinical Trial

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

Study acronym: RASMUS
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-08
Trial Details
NCT Number NCT07527195
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 100 participants
Start Date 2026-04-10
Primary Completion 2028-04-28 (estimated)
Study Completion 2028-06-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-07